Legacy Capital Wealth Partners LLC Sells 309 Shares of Cencora, Inc. $COR

Legacy Capital Wealth Partners LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR) by 12.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,251 shares of the company’s stock after selling 309 shares during the period. Legacy Capital Wealth Partners LLC’s holdings in Cencora were worth $675,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New York State Common Retirement Fund increased its holdings in Cencora by 20.2% during the 2nd quarter. New York State Common Retirement Fund now owns 139,971 shares of the company’s stock worth $41,970,000 after purchasing an additional 23,477 shares in the last quarter. West Family Investments Inc. boosted its position in shares of Cencora by 20.1% during the second quarter. West Family Investments Inc. now owns 3,758 shares of the company’s stock valued at $1,127,000 after buying an additional 630 shares during the last quarter. Schroder Investment Management Group grew its holdings in Cencora by 19.6% during the second quarter. Schroder Investment Management Group now owns 278,883 shares of the company’s stock worth $83,623,000 after buying an additional 45,666 shares in the last quarter. Norges Bank purchased a new stake in Cencora in the 2nd quarter valued at $695,215,000. Finally, Quadrature Capital Ltd purchased a new stake in Cencora in the 2nd quarter valued at $241,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on COR shares. Wells Fargo & Company lifted their price objective on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Mizuho boosted their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research report on Tuesday. Finally, TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at $24,105,113.44. The trade was a 7.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is currently owned by insiders.

Cencora Trading Up 0.1%

Shares of COR stock opened at $368.93 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The firm has a market cap of $71.53 billion, a P/E ratio of 37.96, a PEG ratio of 1.56 and a beta of 0.63. The company has a 50 day moving average of $335.71 and a 200-day moving average of $307.63. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the prior year, the business earned $3.34 earnings per share. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.